Comparative Pharmacology
Head-to-head clinical analysis: PITAVASTATIN CALCIUM versus ZYPITAMAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PITAVASTATIN CALCIUM versus ZYPITAMAG.
PITAVASTATIN CALCIUM vs ZYPITAMAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, reducing cholesterol synthesis in the liver and increasing LDL receptor expression.
ZYPITAMAG (pitavastatin magnesium) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to reduced intracellular cholesterol and upregulation of LDL receptors.
1-4 mg orally once daily
2-4 mg orally once daily, at any time of day, with or without food.
None Documented
None Documented
The terminal elimination half-life is approximately 12 hours (range 9–16 hours), supporting once-daily dosing.
Terminal elimination half-life: 12 hours (range 10-14 h) in healthy subjects; supports once-daily dosing
Approximately 79% of the dose is excreted in feces (as parent drug and metabolites) via biliary elimination, and about 15% is excreted in urine. Less than 2% is excreted unchanged in urine.
Primarily renal (93% as unchanged pitavastatin and metabolites) via active tubular secretion; fecal (5%)
Category D/X
Category C
Statin
Statin